Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02417753 · ClinicalTrials.gov registry record · Phase 2
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02417753: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02417753 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02417753, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Background: \- Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites. This may also treat the cancer. Objective: \- To look at the immune markers the ascites of people with gastrointestinal or ovarian cancer. Eligibility: \- Adults age 18 and older with a malignancy of the gastrointestinal tract (GI) tract or metastatic ovarian cancer. As a result, they have ascites in the abdomen. Design: * Participants will be screened with: * Medical history, physical exam, and blood tests. * Echocardiogram: sound waves make images of the heart. * Electrocardiogram: measures electrical activity of the heart. * Paracentesis: a needle will be inserted in the abdomen and will remove some of the ascites fluid. * They may have a tumor biopsy. * Participants will get AZD9150 through a vein for 3 hours. They will get this 6 times in cycle 1 and 4 times all other cycles. Each cycle is 28 days. * Each cycle, participants will: * Have a physical exam. * Have blood tests weekly. * Be asked about how they feel and any medicines they are taking. * After every 2 cycles (about every 2 months), participants will have scans and x-rays of their tumor. * Participants will have paracentesis 2 more times during the study. They will have another echocardiogram. * At the end of therapy, participants will have a physical exam and blood tests. They will be asked about how they feel and any medicines they are taking.
Interventions
- DRUG AZD9150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-04-03 |
| Est. Completion | 2016-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02417753
The ClinicalTrials.gov registry entry for NCT02417753 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD9150 is the first listed.
NCT02417753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02417753 about?
NCT02417753 is a clinical study titled "AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites". Background: \- Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites. This may also treat the cancer. Objective: \- To look at the immune markers t...
What is the current status of trial NCT02417753?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-04-03. Estimated completion is 2016-04-07.
What interventions are being tested in trial NCT02417753?
The interventions under investigation include: AZD9150 (DRUG).
Who is sponsoring clinical trial NCT02417753?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.